



HEALTH



***Studies of Initial E-Prescribing Standards  
in the  
New Jersey E-Prescribing Action Coalition***

**Douglas S. Bell**

**Testimony to the National Committee on Vital and Health  
Statistics, Standards and Security Subcommittee**


**May 1, 2007**

# *Participating Organizations*


- **New Jersey E-prescribing Action Coalition**
  - **Health plan/Payers**
    - **Horizon BCBSNJ**
    - **Caremark Rx**
  - **E-prescribing vendors**
    - **iScribe**
    - **Allscripts**
    - **InstantDx**
  - **Intermediaries**
    - **RxHub**
    - **SureScripts**
  - **Evaluation**
    - **RAND**
    - **Point of Care Partners**
    - **UMDNJ**
- **MDs from Horizon BCBSNJ “E-Prescribe” program**
  - **Install + pay honorarium for use; 1000 MDs**

# Conceptual Model

- **Structure of the standard**



- **Information display / capture at prescriber**



- **Changes in work processes**



- **Changes in drug use**

- Appropriateness
- Costs
- Patient adherence

- **Other effects**

- Labor and other costs
- Health service use
- Patient satisfaction

STANDARD	METHODOLOGY
<ul style="list-style-type: none"> <li>• Medication History transaction of NCPDP SCRIPT, 8.1</li> <li>• NCPDP Formulary and Benefit, 1.0</li> </ul>	<ul style="list-style-type: none"> <li>• Work process model</li> <li>• <b>Expert panel</b></li> <li>• Physician, pharmacy site visits</li> <li>• <b>Claims data analysis</b></li> <li>• <b>Physician web survey</b></li> </ul>
<p>Fill Status Notification transaction of NCPDP SCRIPT, 8.1</p>	<ul style="list-style-type: none"> <li>• <b>Focus group evaluation of storyboard prototypes</b></li> <li>• <b>Expert panel</b></li> <li>• Work process model</li> </ul>
<p><u>Prior Authorization</u>  ASC X12N 278  ASC X12N 275 wrapper with HL7 attachment</p>	<ul style="list-style-type: none"> <li>• <b>Comparison of existing forms with HL7 standard</b></li> <li>• Work process model</li> <li>• Live pilot study</li> <li>• Physician web survey</li> <li>• Physician site visits</li> </ul>
<p>RxNorm (July, Nov. 2006 versions)</p>	<ul style="list-style-type: none"> <li>• <b>Lab analysis of coverage for a retrospective sample of Rx data</b></li> <li>• Expert panel</li> <li>• Work process model</li> </ul>
<p>Structured and Codified Sig, 1.0  (June 2006 draft)</p>	<ul style="list-style-type: none"> <li>• <b>Lab analysis of coverage for a retrospective sample of Rx data</b></li> </ul>

# ***Medication History: Expert Panel***

- **Technical problems hinder reconciliation of Medication History with prescriptions that the POC originated**
  - **Many fields are optional and often left empty**
    - **Prescriber ID, *Sig*, quantity dispensed, pharmacy**
  - **NDC codes are poor drug identifiers**
    - **Often cannot be mapped to POC's drug compendium**
  - **Patient IDs must first be retrieved from 270/271 Eligibility**
    - **About half of Eligibility checks fail**
- **Some vendors had given up on reconciling Medication History**
  - **Drive alerts only from prescriptions that they originated**
  - **All enthusiastically support developing RxNorm**

# Medication History: Prescriber Survey

- 411 MDs recruited, 395 eligible, 58% response
  - 139 e-prescribers
  - 89 non e-prescribers (from waiting list for eRx)
- Information I have about medication history enables:  
(agree or strongly agree)

	<u>eRx</u>	<u>non eRx</u>
– Identifying clinically important DDIs	83%*	67%
– Prevent callbacks for safety problems	68*	54
– Identify medications from other MDs	65	61
- Among e-prescribers
  - 37% familiar with accessing Medication History; of these:
    - 16% used it often or very often
    - 39% agree data is complete for most patients

## *F&B: Technical Issues*

- **Plan IDs: reliance on Eligibility; no cross-ref**
- **NDC Codes: mismatches, redundancy**
- **Plan-level coverage  $\neq$  Group- or patient- level**
- **Variance in use among PBMs:**

<u>Component</u>	<u>Downloads/mo</u>
formulary status list (FSL)	728
alternative suggestions (ALT)	89
coverage limitations (COV)	21
patient co-pay information (COP)	2

# F&B: Prescriber Survey

In an average week, how many calls or messages do you get about prescription drug coverage problems? (%)

(*P* = 0.10)

	None	1-5	6-10	11-15	>15	E.V.
Non-eRx	1	43	27	10	19	8.1
eRx	1	32	42	13	12	7.9

For an average day that you see patients, how much time do you spend dealing with prescription drug coverage problems? (%)

(*P* = 0.73)

	<5 min	5-15 min	16-30 min	31-60 min	>1 hr
Non-eRx	13	43	28	11	4
eRx	15	44	29	11	1



# *F&B: Prescriber Survey*

## Among e-prescribers:

<b>• Drug coverage information...</b>	<b><u>Disagree</u></b>	<b><u>Neutral</u></b>	<b><u>Agree</u></b>
– Helped me manage patient costs	<b>23%</b>	<b>37%</b>	<b>39%</b>
– Reduced need to change Rx	<b>27</b>	<b>39</b>	<b>34</b>
– Reduced calls re: coverage	<b>30</b>	<b>41</b>	<b>29</b>
– Saves me time	<b>29</b>	<b>41</b>	<b>30</b>
– Reduces costs for my office	<b>31</b>	<b>50</b>	<b>19</b>
– Overall, satisfied	<b>25</b>	<b>38</b>	<b>37</b>

# F&B: Claims Analysis

	<u>n</u>
• eRx-group physicians	<b>319</b>
0 - 12.5 eRx/mo	167
12.5 - 50 eRx/mo	91 (29%)
> 50 eRx/mo	61 (19%)
– Continuously enrolled patients	28,364
• Prescription claims	402,068
– New ACE inhibitor starts	1114
• Control-group physicians	<b>2092</b>
– Continuously enrolled patients	2,382,865
• prescription claims	2.2 million
– New ACE inhibitor starts	5973

# Factors Associated with Generic Start

- **Probability of Generic for New ACE Inhibitor Rx**

	<u>OR</u>	<u>(95% CI)</u>	<u>P</u>
• Time (quarter)	1.1	1.07 - 1.14	<.0001
• Pt. income (per \$10k)	0.96	0.92 – 1.0	.05
• Rx volume (<300/mo)	1.3	1.1 – 1.6	.01
• <b>Post-activation x</b>			
<b>high user (&gt; 50/mo)</b>	<b>2.3</b>	<b>1.1 - 4.6</b>	<b>.02</b>
<b>medium user (12.5-50)</b>	<b>ns</b>		
<b>low user (0-12.5/mo)</b>	<b>ns</b>		
• <b>Also ns: Pt. age, race, gender; MD specialty</b>			

# Extent of E-Prescribing Use

To what extent do you use the e-prescribing system? (%)

iScribe

Allscripts

I use the system to write all of my prescriptions (except DEA Schedule II medications)	48	34
I use the system to write some prescriptions	40	47
I no longer use the system	12	18

Does your staff use e-prescribing to transmit new prescriptions or renewals? (%)

Partial users

Non-users

Yes	34%	66%
No, my staff does not use the system	0%	100%

# Reasons for Continuing to Use Paper Prescriptions

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Patients were not in the PDA	5	8	5	47	36
I can't use the PDA because of technical problems (e.g. network connectivity)	3	3	6	37	51
I get too busy	10	17	7	35	31
Pharmacies don't reliably receive and process the prescriptions I send electronically	8	13	33	36	10
System interfered with established office workflow	16	34	22	22	7
System takes too much of my time	15	24	19	30	13
System takes too much of my staff's time	24	32	30	9	6

RAND

Douglas S. Bell, 5/1/2007

# *Fill Status: Expert Panel*

- **Originating SCRIPT reference number is an optional field**
- **No marketplace demand**
  - “Even if a physician wants it, who is going to pay for it?”
- **Burden of handling opt-in or opt-out requests**
  - “The process of setting-up and maintaining the [opt-in or opt-out] indicator would be significant. Numerous interfacing systems would need to change.”
  - “That’s something that can be designed for and I think that having a patient opt in or out of this is probably something on which we should do more research.”
- **Dispensed & not-dispensed messages both unreliable**
  - “If patients are opting-in or opting-out ... then [if] the physician doesn’t get a ‘filled’ response what does the physician know? Maybe I opted out. They can’t really determine that it was filled, and they can’t determine that it wasn’t filled.”

## *Fill Status: Focus groups*

- **Allscripts users presented with storyboard prototypes displaying adherence alerts**
- **Significant concerns expressed:**
  - **Implied need for telephone follow up**
    - **New, unpaid work for physicians and staff**
  - **Medico-legal liability for non-adherence**
- **Possible mitigating factors:**
  - **Prescriber controls Rx's alerted, time interval**
  - **Deliver alerts during follow-up visit**
    - **Medication history data might substitute**

# *Prior Authorization*

- **Strong demand for process improvements**
  - 91% of MDs surveyed agreed or strongly agreed that the PA process is frustrating, both for them and for patients**
  - “I hate prior authorizations... because of the time they take.”**
  - “Basically, you have to say what the insurance people want to hear.”**      **“I frequently lie, yell or scream.”**
- **Few of the data elements in the HL7 PA Attachment were useful in Horizon’s PA processes**
  - **Wording of PA questions → meaning of data**
  - **ICD-9 codes usually inadequate to capture meaning**
- **Developed prototype modules for iScribe, Allscripts**
  - **Very little use during 8-10 weeks**



# *RxNorm Lab Evaluation*

- **First DataBank, MediSpan, RAND (using RxNorm distribution) independently attempted to match an SCD for new and renewal Rxs**
  - **Non-matches**
    - **9789 non-device new prescriptions**
      - **148 (1.5%) no matching SCD found; 93% multi-vitamins, bowel preps, drugs packaged in a drug delivery device**
      - **8956 (91.5%) matched by 3 of 3**
    - **10,035 non-device renewal requests**
      - **47 (0.5%), did not match to an SCD; 96% in categories above**
      - **9777 (97.4%) matched by all 3**
  - **Mismatches**
    - **592 of 9510 new Rx with 2+ SCD matches (6.2%)**
    - **411 of 9940 renewal requests with 2+ SCD matches (4.1%)**
- Root causes:**
- **Previously recognized & corrected synonyms (20%)**
  - **Previously unrecognized synonymy (30%)**
  - **Errors in NDC-to-SCD mappings used by one of the matching efforts**

# Structured and Codified Sig

- Sampled 42 *Sig* text strings from 10000 new Rx's
  - Each mapped into *Sig* standard by 3 independent reviewers
- For 15 without use of a repeat, poor agreement
 

	<u>3</u>	<u>2</u>	<u>0</u>
– Repeating sig			
– Dose	3	10	2
– Dose calculation		not used	
– Vehicle	1	0	14
– Route	0	1	14
– Site	0	3	12
– Frequency	1	6	8
– Admin timing	0	2	13
– Interval	4	7	14
– Duration			
– Indication	0	2	13
– Stop			
– Free text	0	9	6
- “Repeating Sig” used for 27 (64%) by at least one
  - 1 to 6 iterations used; varied widely
- No reviewers correctly used the modifier fields for variable dosing or variable frequency

# *Conclusions*

- **Medication history, Formulary and Benefit**
  - Technically adequate
  - Falling short of their promise as currently used
- **Fill status**
  - Significant concerns; promise for focused uses
- **Prior authorization**
  - Research on representing data for PA decision
- **RxNorm**
  - Needed; holds significant promise
- **Sig**
  - Difficult to use consistently; suggest simplifying

# Technical Expert Panel

	Category	Company	Primary Contact
	EHR	<b>Allscripts</b>	Jill Helm
Point of care software vendors	eRx	<b>iScribe</b>	Linda Schilling
	eRx	<b>InstantDx</b>	Krishnan Seshadri
	EHR	MedPlus	Rohit Nayak
Content Providers	eRx	ZixCorp	David Robertson
		First DataBank	Tom Bizzaro, RPh
		Wolters Kluwer	Karen Eckert, RPh
		<b>RxHub</b>	Teri Byrne
Intermediaries		<b>SureScripts</b>	Ken Whittemore, RPh
		NDC	Warren Williams
Pharmacies	Mail	<b>Caremark Mail</b>	Jane Niemtschk
	Mail	Medco Mail	Michele Glynn
	Large Chain	<b>Walgreens</b>	Mike Simko, RPh
	Medium Chain	Ahold/Stop&Shop	Brad Dayton, RPh
	Independent	QS1	Tammy Devine